PE20120319A1 - Composiciones adyuvantes que comprenden un agente de isotonicidad no ionico - Google Patents
Composiciones adyuvantes que comprenden un agente de isotonicidad no ionicoInfo
- Publication number
- PE20120319A1 PE20120319A1 PE2011002071A PE2011002071A PE20120319A1 PE 20120319 A1 PE20120319 A1 PE 20120319A1 PE 2011002071 A PE2011002071 A PE 2011002071A PE 2011002071 A PE2011002071 A PE 2011002071A PE 20120319 A1 PE20120319 A1 PE 20120319A1
- Authority
- PE
- Peru
- Prior art keywords
- concentration
- ionic
- isotonicity agent
- compositions including
- adjuvant compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000002671 adjuvant Substances 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 abstract 1
- 241000588650 Neisseria meningitidis Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 102000036673 PRAME Human genes 0.000 abstract 1
- 108060006580 PRAME Proteins 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION INMUNOGENICA QUE COMPRENDE: A) UNA COMPOSICION ADYUVANTE ACUOSA QUE CONTIENE i) UN AGONISTA DEL RECEPTOR TIPO TOLL (TLR-4) TAL COMO MONOFOSFORILO-LIPIDO A 3-DESACILADO (3D-MPL) Y UNA SAPONINA TAL COMO QS21 EN UNA FORMULACION LIPOSOMAL; ii) UN AGENTE DE ISOTONICIDAD NO IONICO TAL COMO SORBITOL EN UNA CONCENTRACION DE 3 A 15% P/V, EN DONDE LA CONCENTRACION DE CLORURO DE SODIO O CONCENTRACION IONICA ES MENOR DE 100mM; B) UN ANTIGENO TAL COMO PRAME, NY-ESO-1 O UNA PREPARACION ANTIGENICA QUE SE DERIVA A PARTIR DE VIH, NEISSERIA MENINGITIDIS O UN ANTIGENO ASOCIADO A UN TUMOR; C) UN OLIGONUCLEOTIDO DE CPG. DICHA COMPOSICION ADYUVANTE SE PUEDE COMBINAR CON UN RANGO MAS AMPLIO DE ANTIGENOS DE PROTEINA INCLUYENDO LOS QUE SON SUSCEPTIBLES A LA EXTRACCION CON SAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0910046.2A GB0910046D0 (en) | 2009-06-10 | 2009-06-10 | Novel compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120319A1 true PE20120319A1 (es) | 2012-04-16 |
Family
ID=40937237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011002071A PE20120319A1 (es) | 2009-06-10 | 2010-06-08 | Composiciones adyuvantes que comprenden un agente de isotonicidad no ionico |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20120087976A1 (es) |
| EP (1) | EP2440242B1 (es) |
| JP (3) | JP5647677B2 (es) |
| KR (1) | KR101473686B1 (es) |
| CN (2) | CN104367997B (es) |
| AU (1) | AU2010257538B2 (es) |
| BR (1) | BRPI1012890B1 (es) |
| CA (1) | CA2764421C (es) |
| CL (1) | CL2011003113A1 (es) |
| CO (1) | CO6440528A2 (es) |
| CY (1) | CY1115522T1 (es) |
| DK (1) | DK2440242T3 (es) |
| DO (1) | DOP2011000346A (es) |
| EA (1) | EA024074B1 (es) |
| ES (1) | ES2494442T3 (es) |
| GB (1) | GB0910046D0 (es) |
| HR (1) | HRP20140792T1 (es) |
| IL (1) | IL216231A0 (es) |
| MA (1) | MA33412B1 (es) |
| MX (1) | MX2011013162A (es) |
| MY (1) | MY159819A (es) |
| NZ (1) | NZ596503A (es) |
| PE (1) | PE20120319A1 (es) |
| PL (1) | PL2440242T3 (es) |
| PT (1) | PT2440242E (es) |
| RS (1) | RS53550B1 (es) |
| SG (1) | SG176638A1 (es) |
| SI (1) | SI2440242T1 (es) |
| SM (1) | SMT201400134B (es) |
| UA (1) | UA104888C2 (es) |
| WO (1) | WO2010142685A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58855B1 (sr) | 2009-06-10 | 2019-07-31 | Chugai Pharmaceutical Co Ltd | Tetraciklična jedinjenja |
| JP4918630B1 (ja) | 2010-08-20 | 2012-04-18 | 中外製薬株式会社 | ４環性化合物を含む組成物 |
| EP3023106B1 (en) | 2010-12-14 | 2019-07-31 | GlaxoSmithKline Biologicals S.A. | Mycobacterium antigenic composition |
| MX389105B (es) | 2012-09-25 | 2025-03-20 | Chugai Pharmaceutical Co Ltd | Inhibidor de quinasas reordenadas durante la transfeccion (ret). |
| CN107124869B (zh) * | 2014-03-25 | 2022-04-01 | 美国政府陆军部 | 包含含有单磷酰脂质a（mpla）的脂质体组合物和皂苷的无毒佐剂制剂 |
| CN106456651A (zh) | 2014-04-25 | 2017-02-22 | 中外制药株式会社 | 以高用量含有四环性化合物的制剂 |
| KR20220042486A (ko) | 2014-04-25 | 2022-04-05 | 추가이 세이야쿠 가부시키가이샤 | 4환성 화합물의 신규 결정 |
| TWI718102B (zh) | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體 |
| CA2973857C (en) | 2015-01-16 | 2023-11-07 | Chugai Seiyaku Kabushiki Kaisha | Combination drug |
| IL286493B (en) | 2015-11-06 | 2022-07-01 | Memorial Sloan Kettering Cancer Center | Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof |
| WO2018104313A1 (en) * | 2016-12-07 | 2018-06-14 | Glaxosmithkline Biologicals Sa | Novel process |
| JP2020521781A (ja) | 2017-05-30 | 2020-07-27 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | リポソームに内包されたｒｎａを製造する方法 |
| AU2018350887A1 (en) | 2017-10-16 | 2020-03-05 | Adjuvance Technologies, Inc. | Triterpene saponin analogues |
| CN111670044A (zh) * | 2017-12-01 | 2020-09-15 | 葛兰素史密丝克莱恩生物有限公司 | 皂苷纯化 |
| MX2020005480A (es) | 2017-12-01 | 2020-12-07 | Glaxosmithkline Biologicals Sa | Extraccion de saponina. |
| IL281079B2 (en) | 2018-09-04 | 2024-12-01 | Chugai Pharmaceutical Co Ltd | Method of producing a tetracyclic compound |
| WO2020109365A1 (en) * | 2018-11-29 | 2020-06-04 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
| WO2021023692A1 (en) * | 2019-08-05 | 2021-02-11 | Glaxosmithkline Biologicals Sa | Process for preparing a composition comprising a protein d polypeptide |
| WO2021038508A1 (en) | 2019-08-30 | 2021-03-04 | Glaxosmithkline Biologicals Sa | Jet mixing lipid nanoparticle manufacturing process |
| JP7599258B1 (ja) * | 2023-03-15 | 2024-12-13 | ユナイテッド・イミュニティ株式会社 | 脂質粒子 |
| WO2025180443A1 (en) * | 2024-02-29 | 2025-09-04 | Immunadd Inc. | Adjuvant composition, pharmaceutical composition comprising the same, and method for preventing or treating disease caused by viral infection, bacterial infection, protozoal infection or cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
| CZ289476B6 (cs) * | 1993-03-23 | 2002-01-16 | Smithkline Beecham Biologicals (S.A.) | Očkovací přípravek a způsob jeho výroby |
| UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| DE19803453A1 (de) * | 1998-01-30 | 1999-08-12 | Boehringer Ingelheim Int | Vakzine |
| DK1584685T3 (da) | 1998-02-05 | 2011-07-11 | Glaxosmithkline Biolog Sa | Tumorassocieret antigenderivater fra Mage-familien, anvendt til fremstilling af fusionsproteiner med T-hjælper epitoper og sammensætninger til vaccination |
| HU225844B1 (en) * | 1998-05-07 | 2007-10-29 | Corixa Corp | Adjuvant composition and its use |
| JP3765232B2 (ja) | 2000-11-16 | 2006-04-12 | 株式会社ジェイテクト | 電動式パワーステアリング装置及びこれに用いる歯車の製造方法 |
| GB0409940D0 (en) | 2004-05-04 | 2004-06-09 | Glaxosmithkline Biolog Sa | Vaccine |
| GB0411411D0 (en) * | 2004-05-21 | 2004-06-23 | Glaxosmithkline Biolog Sa | Vaccines |
| JP2008521385A (ja) * | 2004-11-29 | 2008-06-26 | 長春華普生物技術有限公司 | アジュバントとしてのＣｐＧ含有一本鎖デオキシヌクレオチド |
| KR101408113B1 (ko) * | 2005-06-27 | 2014-06-16 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 제조 방법 |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| PL2114993T3 (pl) | 2007-01-15 | 2013-01-31 | Glaxosmithkline Biologicals Sa | Szczepionka |
| WO2008089074A2 (en) | 2007-01-15 | 2008-07-24 | Glaxosmithkline Biologicals Sa | Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1 |
| MX2009012381A (es) * | 2007-05-24 | 2009-12-01 | Glaxosmithkline Biolog Sa | Composicion antigenica liofilizada. |
| GB0910045D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
-
2009
- 2009-06-10 GB GBGB0910046.2A patent/GB0910046D0/en not_active Ceased
-
2010
- 2010-06-08 PT PT107210361T patent/PT2440242E/pt unknown
- 2010-06-08 RS RSP20140476 patent/RS53550B1/sr unknown
- 2010-06-08 MY MYPI2011005958A patent/MY159819A/en unknown
- 2010-06-08 CA CA2764421A patent/CA2764421C/en active Active
- 2010-06-08 EP EP10721036.1A patent/EP2440242B1/en active Active
- 2010-06-08 SG SG2011089315A patent/SG176638A1/en unknown
- 2010-06-08 HR HRP20140792AT patent/HRP20140792T1/hr unknown
- 2010-06-08 WO PCT/EP2010/058017 patent/WO2010142685A1/en not_active Ceased
- 2010-06-08 JP JP2012514447A patent/JP5647677B2/ja active Active
- 2010-06-08 ES ES10721036.1T patent/ES2494442T3/es active Active
- 2010-06-08 CN CN201410497386.1A patent/CN104367997B/zh active Active
- 2010-06-08 KR KR1020127000650A patent/KR101473686B1/ko not_active Expired - Fee Related
- 2010-06-08 CN CN201080024992.1A patent/CN102458457B/zh active Active
- 2010-06-08 UA UAA201113798A patent/UA104888C2/uk unknown
- 2010-06-08 EA EA201190286A patent/EA024074B1/ru not_active IP Right Cessation
- 2010-06-08 AU AU2010257538A patent/AU2010257538B2/en not_active Ceased
- 2010-06-08 DK DK10721036.1T patent/DK2440242T3/da active
- 2010-06-08 NZ NZ596503A patent/NZ596503A/xx not_active IP Right Cessation
- 2010-06-08 US US13/377,425 patent/US20120087976A1/en not_active Abandoned
- 2010-06-08 MA MA34506A patent/MA33412B1/fr unknown
- 2010-06-08 PE PE2011002071A patent/PE20120319A1/es not_active Application Discontinuation
- 2010-06-08 BR BRPI1012890-5A patent/BRPI1012890B1/pt active IP Right Grant
- 2010-06-08 SI SI201030689T patent/SI2440242T1/sl unknown
- 2010-06-08 PL PL10721036T patent/PL2440242T3/pl unknown
- 2010-06-08 MX MX2011013162A patent/MX2011013162A/es active IP Right Grant
-
2011
- 2011-11-09 IL IL216231A patent/IL216231A0/en active IP Right Grant
- 2011-11-11 DO DO2011000346A patent/DOP2011000346A/es unknown
- 2011-12-07 CL CL2011003113A patent/CL2011003113A1/es unknown
- 2011-12-12 CO CO11170871A patent/CO6440528A2/es active IP Right Grant
-
2014
- 2014-08-29 CY CY20141100698T patent/CY1115522T1/el unknown
- 2014-09-15 SM SM201400134T patent/SMT201400134B/xx unknown
- 2014-09-26 JP JP2014196018A patent/JP5977789B2/ja active Active
-
2016
- 2016-05-16 JP JP2016097525A patent/JP6261647B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-10 US US15/645,473 patent/US20180021417A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120319A1 (es) | Composiciones adyuvantes que comprenden un agente de isotonicidad no ionico | |
| CO6751288A2 (es) | Composición antigénica de micobacteria | |
| HRP20160816T1 (hr) | Upotreba virusa influence i emulzije ulja u vodi kao adjuvansa radi poticanja t-stanica cd4 i/ili poboljšanog odgovora memorijskih b-stanica | |
| AR113034A2 (es) | Formulación líquida de un conjugado de la hormona del crecimiento humano de efecto prolongado | |
| BRPI1013780B8 (pt) | Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica | |
| CY1123334T1 (el) | Σκευασματα φιναστεριδης για αποδεσμευση φαρμακου στα μαλλια και στο τριχωτο της κεφαλης | |
| EA201001189A1 (ru) | Вакцинные композиции, содержащие сапониновый адъювант | |
| PE20121517A1 (es) | Compuestos lipopeptidos y metodos relacionados | |
| CR10559A (es) | Vacuna de influenza | |
| AR107285A2 (es) | Vacuna | |
| HRP20210242T1 (hr) | Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086 | |
| MX2023013460A (es) | Formulaciones de anticuerpos humanos anti-rankl y metodos de uso de estas. | |
| CO6251369A2 (es) | Vacuna de influenza de emulsion de aceite en agua | |
| MX2019008564A (es) | Composiciones inmunogenicas para su uso en vacunas neumococicas. | |
| AR095396A1 (es) | Formulaciones de anticuerpo | |
| PE20151588A1 (es) | Vacuna contra el virus del dengue | |
| BR112015001313A2 (pt) | composições de vacina | |
| MX378901B (es) | Formulaciones liquidas estables de virus de vacuna. | |
| PE20110642A1 (es) | Formulaciones antifungicas topicas a base de terbinafina y compuestos similares a terbinafina y metodos de uso | |
| PH12018502403A1 (en) | Hiv vaccine formulation | |
| BRPI0520330A2 (pt) | adjuvante a base de ácido polinosìnico-policitidìlico | |
| BR112015014174A2 (pt) | composição de vacina para indivíduos virgens | |
| CO6660486A2 (es) | Composición tópica famacéutica o cosmética útil para el tratamiento de enfermedades o condiciones que cursan con un déficit de la maduración de la envoltura córnea | |
| BRPI0820960B8 (pt) | composição, composição farmacêutica, e uso da composição | |
| ES2570310T3 (es) | Composiciones para la vacunación por vía cutánea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |